Purpose: Leptin promotes the fi brogenic eff ect of hepatic stellate cells (HSCs). Galanin is another endogenous factor involved in regulating bioenergic metabolism conteracting a majority eff ects of leptin. However, little is known about the eff ects of galanin on HSCs. Th e current study is aimed to investigate the biological eff ects of galanin on HSCs. Methods: HSCs isolated from male Sprague Dawley rats by in situ perfusion were cultured for 0 weeks or 2 weeks. Cells were then harvested and the mRNA expression of galanin and galanin receptors were examined by RT-PCR. Immunocytofl uorescence were used to confi rm the presence of GalR2 protein on HSCs. Cultured HSCs-T6 were subjected to galanin at the concentration of 1 to 10000 nmol/L for 24 hours. Cell proliferation was examined by MTT assay and a working concentration for the following experiment was determined. Cultured HSCs-T6 were divided to four groups: control, galanin treatment group (galanin 100nmol/L), GalR2 small interfering RNA (siRNA) treatment group (GalR2 siRNA+Galanin) and GalR3 siRNA treatment group (GalR3 siRNA+Galanin). Th e proliferation of HSCs-T6 was tested by MTT assay. Western blot was used to detect transforming growth factor β1 (TGF-β1), α-smooth muscle akin (α-SMA) and peroxisome proliferatoractivated receptor gamma (PPAR-γ) in all groups. Results: Galanin mRNA and GalR3 mRNA were all expressed by both quiescent and activated HSCs. Importantly, GalR2 mRNA was undetectable in quiescent HSCs but was markedly expressed by activated HSCs. GalR1 mRNA was not detected in either quiescent or activated HSCs. Th e presence of GalR2 protein on activated HSC was further confi rmed by immunocytofl uorescence. Treatment with galanin of low concentrations(1-100nmol) inhibited HSCs-T6 proliferation in a concentration-depended manner (P<0.05). Galanin (100 nmol/L) signifi cantly inhibited cell proliferation (P<0.05), TGF-β1 and α-SMA expression, but upregulated PPAR-γ expression (P<0.05). When compared to controls, GalR2 knockdown in HSC-T6 showed no eff ect on cell proliferation, TGF-β1 and α-SMA protein expression, in contract to a increase in PPARγ expression (p<0.05). However, GalR3 knockdown resulted in decreases in HSC-T6 proliferation, TGF-β1 and α-SMAprotein expression but a increase in PPAR-γ expression (P<0.05). Conclusion: Galanin receptors are diff erentially expressed by HSCs of diff erent activation status. Galanin downregulates HSCs activation and suppresses its profi brogenic features. Th e underlying mechanisms may involve inhibition of HSC proliferation, decrease in TGF-β1 expression and increase in PPARγ expression. Th ese biological functions of galanin are very likely mediated by type 2 receptor GalR2.
decompensations, many patients lack the capacity to make their own medical decisions. Our study looks at the factors that correlate with a patient making plans for those eventualities. Methods: We reviewed the medical records of 1055 patients whom carried the diagnosis of hepatic cirrhosis based on a computerized review of patients seen between 2002 and 2011. We performed a cross sectional study of the use of advanced directives and/or power of attorney in relation to the severity of their disease. We also did subset analysis on other factors including, age, race, gender and household income to see if these factors infl uence the use of advanced planning instruments (API). Results: Our data shows that advanced directive status was addressed in 66% of patients. High MELD score, and therefore advanced disease, did not correlate in a clinically signifi cant way with increased use of advanced directives.(OR 1.03, r 0.02, CI 1.00-1.06) In addition neither did age (OR 0.97, r 0.01, CI .94-.99), race (OR 1.10, r 0.62, CI 0.75-1.63), gender (OR 0.99, r 0.97, CI 0.71-1.39) or poverty rate (OR 1.00, r 0.99, CI 0.97-1.03). Conclusion: MELD scores can accurately predict mortality in a large percentage of cirrhotic patients. A MELD score of over 30 for example, predicts a 90 day mortality of approximately 50%. A MELD of 12 meets criteria for transplant referral at our institution. Th e lack of correlation between MELD and advanced directives may refl ect a lack of understanding of the patient as to the severity of their disease, or could be a refl ection of the patient already being incapacitated by their disease and unable to make decisions. It is also possible this trend refl ects cultural attitudes and beliefs about death and dying and the use of durable healthcare documents. Finally, and probably most concerning, it may refl ect a lack of information available to the patient. Th e authors believe as a "best practice" that the issue of advanced directives should be brought up to every patient at the initial diagnosis of cirrhosis. We are currently conducting further research to identify the best manner to implement this and measure the eff ects of increased use of advanced directives. Th e project described was supported by Grant Number M01 RR00080 and Grant Number UL1 RR024989 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and its contents are solely the responsibility of the authors and do not necessarily represent the offi cial view of NCRR or NIH.
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Characterization of Hepatocellular Carcinoma in an Inner City Afro-Caribbean Patient Population
Asra Batool, MD, Mahwish Nida, MD, Madalina Butnariu, MD, Veronika Dubrovskaya, MD, Frank Gress, MD. SUNY Downstate Medical Center, Brooklyn, NY. Purpose: Hepatocellular carcinoma (HCC) is the fi ft h most common cancer worldwide. Th e literature lacks data on HCC in the Afro Caribbean community. Aim is to study the characteristics and natural history of HCC in Afro Caribbean patients in an urban academic medical center. Methods: A retrospective review of ICD-9 codes was performed to identify patients with HCC evaluated at 2 academic teaching hospitals in Brooklyn, NY between 1999-2010. Both hospitals are located in a community of Afro-Caribbean immigrants. 
